Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis

Rhinology

Volumn 43, Issue 4, 2005, Pages 291-295

  Barnes, Martyn L ^a   Biallosterski, Bart T ^a   Gray, Robert D ^a   Fardon, Tom C ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Allergy; Mometasone; Persistent; Rhinitis; Xylometazoline

Indexed keywords

MOMETASONE FUROATE; PLACEBO; XYLOMETAZOLINE;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; EPISTAXIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; INSPIRATORY RESERVE VOLUME; MALE; PERSISTENT INFECTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INTRANASAL; ANTI-ALLERGIC AGENTS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIDAZOLES; MALE; NASAL DECONGESTANTS; PREGNADIENEDIOLS; RHINITIS, ALLERGIC, PERENNIAL; SPIROMETRY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 29744437071     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bousquet J, Van Cauwenberge P, Khaltaev N (2001) Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108 (5 Suppl): S147-334.
2. Dykewicz MS, Fineman S, Skoner DP et al. (1998) Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81: 478-518.
3. Graf PM, Hallen H (1998) Changes in nasal reactivity in patients with rhinitis medicamentosa after treatment with fluticasone propionate and placebo nasal spray. ORL J Otorhinolaryngol Relat Spec 60: 334-338.
4. Lin CY, Cheng PH, Fang SY (2004) Mucosal changes in rhinitis medicamentosa. Ann Otol Rhinol Laryngol 113: 147-151.
5. Graf P (1997) Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy 52 (40 Suppl): 28-34.
6. Brooks CD, Titus CF, Heissler CT (1988) Vasoconstrictor and corticosteroid responsive components of allergic nasal mucosal swelling. Ann Allergy 61: 151-156.
7. McKenzie AW, Stoghton RB. (1962) Method for comparing percutaneous absorption of steroids. Arch Dermatol 86: 608-610.
8. Kerstjens HA, Overbeek SE, Schouten JP, Brand PL, Postma DS (1993) Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Respir J 6: 868-76.
9. Bronsky EA, Aaronson DW, Berkowitz RB, et al. (1997) Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 79: 51-56.
10. Sims EJ, Wilson AM, White PS, Gardiner Q, Lipworth BJ (2002) Short-term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. Rhinology 40: 66-68.
11. Wilson AM, Sims EJ, Robb F, Cockburn W, Lipworth BJ (2003) Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology 41: 16-20.
12. Oluwole M, Gardiner Q, White PS (1997) The naso-oral index: a more valid measure than peak flow rate? Clin Otolaryngol 22: 346-349.
13. Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods Med Res 8: 135-160.
14. Stuck BA, Blum A, Hagner AE, Hummel T, Klimek L, Hormann K (2003) Mometasone furoate nasal spray improves olfactory performance in seasonal allergic rhinitis. Allergy 58: 1195.
15. Gawchik S, Goldstein S, Prenner B, John A (2003) Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 90: 416-421.
16. Bende M, Carrillo T, Vona I, da Castel-Branco MG, Arheden L (2002) A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol 88: 617-623.
17. Meltzer EO, Jalowayski AA, Orgel HA, Harris AG (1998) Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol 102: 39-49.
18. Watanabe H, Foo TH, Djazaeri B, Duncombe P, Mackay IS, Durham SR (2003) Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis. Rhinology 41: 167-174.
19. Haigh RM, Jones CT (1990) Effect of glucocorticoids on alpha 1-adrenergic receptor binding in rat vascular smooth muscle. J Mol Endocrinol 5: 41-48.
20. Eickelberg O, Roth M, Lorx R et al. (1999) Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274: 1005-1010.
21. Roth M, Johnson PR, Rudiger JJ et al. (2002) Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360: 1293-1299.
22. Elwany S, Abdel-Salaam S (2001) Treatment of rhinitis medicamentosa with fluticasone propionate--an experimental study. Eur Arch Otorhinolaryngol 258: 116-119.
23. Ferguson BJ, Paramaesvaran S, Rubinstein E (2001) A study of the effect of nasal steroid sprays in perennial allergic rhinitis patients with rhinitis medicamentosa. Otolaryngol Head Neck Surg 125: 253-260.
24. Tan KS, McFarlane LC, Lipworth BJ (1998) Concomitant administration of low-dose prednisolone protects against in vivo beta2-adrenoceptor subsensitivity induced by regular formoterol. Chest 113: 34-41.